Open Access<p>Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report</p>
Author(s) -
Gang Li,
Hongfei Ge,
Zhengqing Yan,
Guoqiang Wang,
Xiaomai Wu,
Dongqing Lv
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s228726
Subject(s) - afatinib , medicine , oncology , docetaxel , lung cancer , carboplatin , gemcitabine , cancer , chemotherapy , erlotinib , epidermal growth factor receptor , cisplatin
HER2 mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases; however, until now, there are no approved standard targeted therapy for NSCLC patients harboring HER2 mutations.